In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr–Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr ...

Medivo Launches Free Mobile App for Monitoring Chronic Myeloid Leukemia (CML) CML Monitor Provides Innovative Method for Tracking Symptoms and Monitoring BCR-ABL Lab Test Results for Physicians ...

Bcr-Abl tyrosine kinase has been validated as a molecular target for the treatment of chronic myelogenous leukemia (CML). More recently, it has been reported that CML patients could develop ...

The Acrometrix BCR-ABL external control panel is launched to quantitate BCR-ABL RNA accurately. The first of its kind, the product is useful to make a critical, timely, patient treatment decisions.

HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I ...

The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab.

Asuragen inked an exclusive agreement with Novartis to develop international scale (IS) calibrators and laboratory software reporting tools for Bcr-Abl1 test results generated from RT qPCR.

Medivo Launches Free Mobile App for Monitoring Chronic Myeloid Leukemia (CML) CML Monitor Provides Innovative Method for Tracking Symptoms and Monitoring BCR-ABL Lab Test Results for Physicians and ...

Medivo Launches Free Mobile App for Monitoring Chronic Myeloid Leukemia (CML) CML Monitor Provides Innovative Method for Tracking Symptoms and Monitoring BCR-ABL Lab Test Results for Physicians ...

Medivo is the emerging, cloud-based, health monitoring platform that connects doctors, consumers and clinical labs. Its unique access to clinical data and advanced analytics simplifies and improves ...